SCHEMBL1380955

SCHEMBL1380955

N#Cc1cccc(C(c2ccccn2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.46
VNN1 O95497 2/20 0.45
KCNA5 P22460 7/20 0.45
KCNH2 Q12809 2/20 0.42
MGLL Q99685 1/20 0.40
GRM5 P41594 4/20 0.39
CLK4 Q9HAZ1 1/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA5 P30532 1/20 0.38
CHRNA4 P43681 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379569 0.90 KCNA5 (0.48) CYP19A1VNN1KCNA5KCNH2MGLL
SCHEMBL3894888 0.90 CHRNB2 (0.41) CYP19A1VNN1KCNA5KCNH2MGLL
SCHEMBL1380001 0.87 CYP19A1 (0.46) CYP19A1VNN1KCNA5KCNH2MGLL
SCHEMBL1377857 0.87 CYP19A1 (0.58) CYP19A1VNN1KCNA5
SCHEMBL1381261 0.85 CYP19A1 (0.49) CYP19A1VNN1KCNA5KCNH2MGLL
SCHEMBL1381350 0.85 CYP19A1 (0.49) CYP19A1VNN1KCNA5KCNH2MGLL
Ammonia Solution, Strong SCHEMBL27668110 0.85 KCNA5 (0.38) CYP19A1VNN1KCNA5KCNH2MGLL
SCHEMBL15014672 0.84 VNN1 (0.37) CYP19A1VNN1KCNA5KCNH2MGLL
SCHEMBL1381791 0.83 KCNA5 (0.60) CYP19A1VNN1KCNA5GRM5
SCHEMBL1380122 0.83 VNN1 (0.46) VNN1KCNA5MGLLGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP claimed
JP-4719744-B2 2011-07-06 JP claimed
EP-1776355-A4 POTASSIUM CHANNEL INHIBITORS MERCK & CO INC (US) 2009-08-12 EP claimed
EP-1776355-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2007-04-25 EP claimed
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias MERCK SHARP & DOHME LLC 2006-02-09 US claimed
WO-2006014877-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2006-02-09 WO claimed
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias MERCK SHARP & DOHME LLC 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias KCNN2, KCNJ2, KCNH2 CYP19A1 4696/4885VNN1 1566/4885KCNA5 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.